• search
Genetic Toxicology Studies Genetic Toxicology Studies

Genetic Toxicology Studies

We are committed to provide rapid and solution-driven genetic toxicology services to the clients.

We characterize the potential genotoxicity of compounds using various test and assays:

In vivo micronucleus test Chromosomal aberration test Traditional Ames assay

The in vivo Micronucleus Assay (in vivo MNT) is a reliable and commonly-employed test to meet the regulatory requirements while submitting IND, to screen the compounds ( such as chemicals, impurities, pesticides, insecticides, food and feed additives) for their clastogenic potential in bone marrow of rodents (rats/mice) and as a component of exposure-based risk assessment. This assay plays a vital role in adding weight of evidence in the hazardous measurement of any chemical and quantitative risk assessments.

The Chromosomal Aberration Test (CAT) is routinely employed as part of NPD and to meet regulatory expectation to screen the compounds ( such as chemicals, impurities, pesticides, insecticides, food and feed additives) for their clastogenic potential to cells (human blood lymphocytes or mammalian cell lines in culture) by evaluating the development gene/chromosome damage in the form of structural aberrations at chromosome level.

Ames test is a rapid and reliable bacterial assay used for evaluating a chemical's potential genotoxicity by measuring its ability to induce reverse mutations at selected loci of modified Salmonella and E. coli bacterial strains. These strains have various mutations and are not capable of synthesizing an essential amino acid, either histidine (Salmonella) or tryptophan (E. coli), so they can only grow in the culture medium that is supplemented with that amino acid. Once the bacteria are exposed to a mutagen, mutation(s) occur that could restore/reverse the ability of the bacteria to synthesize the amino acid and to continue growth even after depletion of traces of provided amino acid in the agar. Relevant mutations involve substitution of individual base pairs or frameshift mutations caused by addition or deletion of a stretch of DNA. The Ames test can be carried out in the presence and absence of a metabolizing system (e.g., Aroclor 1254-induced rat liver S9 fraction) to identify potential mutagenicity by the parent compound and/or its metabolites.

Speak to our experts

In vivo micronucleus test

Young & healthy rats/mice are exposed to the compound of interest at different concentrations derived from dose range finding study. Post treatment, animals will be euthanized and femurs are collected. Bone marrow cells from femurs are isolated and fixed on slides and then staining is performed. Four thousand polychromatic erythrocytes per each animal will be screened to measure the frequency of micronulated - polychromatic erythrocytes.

Positive results demonstrate an increase in the frequency of micronucleated polychromatic erythrocytes in treated animals which is an indication of induced chromosome damage. Increase can be statistically significant and/or dose-dependent.

Chromosomal aberration test

Cells in cultures are exposed to the compound of interest at different concentrations for shorter duration (3-6 hours) and continuously (1.5 cell cycle time) till harvesting. In shorter duration exposure, testing will be performed by supplying liver metabolizing enzymes to evaluate by-products of compound and in other hand absence of metabolism support in shorter and continuous exposures to evaluate direct compound activity.

Positive results demonstrate an increase in the percentage of structural aberrations in comparison with concurrent controls. Increase can be statistically significant and/or dose-dependent.

Traditional Ames assay

Mini Ames

For repeated and multiple screenings, we provide Mini Ames Test by using TA98/TA100/E.coli wp2 strains; Non-GLP screening assay to evaluate the multiple compounds in each step especially where test items are accessible at very less quantity.

Ames-Fluctuation assay

We make the screening much more convenient by adding the one more high-throughput fluctuation assay. The extra added advantage in this service is which requires a very small amount of compound i.e. less than 50 mg. This is a 384-well plate method where Salmonella strains, TA98, TA100, TA1535, and TA1537 will be tested by exposing the test item in the exposure liquid purple color media and mutations indicated as yellow color colonies after incubation.

Why Aurigene Genetic Toxicology Studies Services?

Quick turnaround time

Extensive experience in the genetic toxicology studies

Team of expert analytical and toxicology scientists

State-of-the-art facilities

Virtual Tour

 

Connect with our scientific experts for your drug discovery, development, and manufacturing needs

We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.

Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.

Country
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Resources

PROTACs: Research for a life without cancer

OCTOBER 01, 2024

PROTACs: Research for a life without cancer

PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...

Read More
View All

Advancement in personalized medicine and how the CRDMO industry is part of the solution

Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...

Read More
View All

Cell Line Development

We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...

Read More
View All

Case study: Tackling CYP 2C9 inhibition challenges

The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...

Read More
View All

Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry

2022

Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...

Read More
View All
×

You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.

If you wish to continue to this external website, click Proceed.

ProceedBack

X

Leaving already?

Don't forget to join us at

CPHI Worldwide 2023.

October 24th-26th, 2023 | Barcelona, Spain

Get ready to accelerate your drug’s journey to the market